Back

prof. dr. H.G.M. (Harry) Heijerman

Full Professor
  1. Contact
  2. Research Programs
  3. Research Output
E. hheijer2@umcutrecht.nl
  • Department of Pulmonary Diseases

Research Programs

Infection & Immunity

Research Output (54)

Clinical effects of the three CFTR potentiator treatments curcumin, genistein and ivacaftor in patients with the CFTR-S1251N gating mutation

Berkers Gitte, van der Meer Renske, van Mourik Peter, Vonk Annelotte M, Kruisselbrink Evelien, Suen Sylvia Wf, Heijerman Harry Gm, Majoor Christof J, Koppelman Gerard H, Roukema Jolt, Janssens Hettie M, de Rijke Yolanda B, Kemper E Marleen, Beekman Jeffrey M, van der Ent Cornelis K, de Jonge Hugo R nov 2020, In: Journal of Cystic Fibrosis. 19 , p. 955-961 7 p.

Resting energy expenditure in cystic fibrosis patients decreases after lung transplantation, which improves applicability of prediction equations for energy requirement

Hollander-Kraaijeveld Francis, Van Lanen A.S., de Roos N M, van de Graaf EA, Heijerman Harry nov 2020, In: Journal of Cystic Fibrosis. 19 , p. 975-980 6 p.

Effectiveness of pulmonary rehabilitation at high-altitude compared to sea-level in adults with severe refractory asthma

de Nijs S B, Krop E J M, Portengen L, Rijssenbeek-Nouwens L H, de Vries D, Weersink E J M, Heijerman H G M, Heederik D J J, Lammers J W J sep 2020, In: Respiratory Medicine. 171 , p. 1-11

Transparency and diversity in cystic fibrosis research - Authors' reply

McCoy Karen S, Heijerman Harry, Taylor-Cousar Jennifer L, Waltz David, Sosnay Patrick R, Ramsey Bonnie W, Rowe Steven, Welter John 29 aug 2020, In: The Lancet. 396 , p. 602 1 p.

Long-term effects of ivacaftor on nonpulmonary outcomes in individuals with cystic fibrosis, heterozygous for a S1251N mutation

Burghard M., Berkers G., Ghijsen S., Hollander-Kraaijeveld F. M., de Winter-de Groot K. M., van der Ent C. K., Heijerman H. G.M., Takken T., Hulzebos H. J. jun 2020, In: Pediatric Pulmonology. 55 , p. 1400-1405 6 p.

Does Circadian Rhythm affect the Pharmacokinetics of Once-Daily Tobramycin in Adults with Cystic Fibrosis?

van Maarseveen E M, van der Meer R, Neef C, Heijerman H G M, Touw D J 11 feb 2020, In: Therapeutic Drug Monitoring. 42 , p. 595-599 5 p.

Clinical effect of lumacaftor/ivacaftor in F508del homozygous CF patients with FEV<sub>1</sub> ≥ 90% predicted at baseline

Aalbers B L, de Winter-de Groot K M, Arets H G M, Hofland R W, de Kiviet A C, van Oirschot-van de Ven M M M, Kruijswijk M A, Schotman S, Michel S, van der Ent C K, Heijerman H G M 7 jan 2020, In: Journal of Cystic Fibrosis. 19 , p. 654-658 5 p.

Females with cystic fibrosis have a larger decrease in sweat chloride in response to lumacaftor/ivacaftor compared to males

Aalbers B. L., Hofland R. W., Bronsveld I., de Winter-de Groot K. M., Arets H. G.M., de Kiviet A. C., van Oirschot-van de Ven M. M.M., Kruijswijk M. A., Schotman S., Michel S., van der Ent C. K., Heijerman H. G.M. 1 jan 2020, In: Journal of Cystic Fibrosis. 20 , p. e7-e11

Forskolin-induced swelling of intestinal organoids correlates with disease severity in adults with cystic fibrosis and homozygous F508del mutations

de Winter-de Groot Karin M, Berkers Gitte, Marck-van der Wilt Rozemarijn E P, van der Meer Renske, Vonk Annelotte, Dekkers Johanna F, Geerdink Margot, Michel Sabine, Kruisselbrink Evelien, Vries Rob, Clevers Hans, Vleggaar Frank P, Elias Sjoerd G, Heijerman Harry G M, van der Ent Cornelis K, Beekman Jeffrey M 14 nov 2019, In: Journal of Cystic Fibrosis. 19 , p. 614-619 6 p.

Home videos of cystic fibrosis patients using tobramycin inhalation powder:Relation of flow and cough

Meerburg Jennifer J, Albasri Mehdi, van der Wiel Els C, Andrinopoulou Eleni-Rosalina, van der Eerden Menno M, Majoor Christof J, Arets Hubertus G M, Heijerman Harry G M, Tiddens Harm A W M nov 2019, In: Pediatric Pulmonology. 54 , p. 1794-1800 7 p.

All research output